‹ Back to screener

POLYMED.NS Poly Medicure Ltd.

Healthcare

Price history

2025-08-21 ₹1964.70
2026-08-21 ₹1727.50
Change over window -12.07%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 51.5%
Trailing 20-day average 47.7%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 197416 101715 51.52%
2026-08-27 109590 45519 41.54%
2026-08-26 91740 51329 55.95%
2026-08-25 78354 36196 46.20%
2026-08-24 95827 37694 39.34%
2026-08-21 96900 54537 56.28%
2026-08-20 93919 61459 65.44%
2026-08-19 100462 44863 44.66%
2026-08-18 224876 123485 54.91%
2026-08-17 157632 74777 47.44%
2026-08-14 139114 75056 53.95%
2026-08-13 122895 63612 51.76%
2026-08-12 219951 93259 42.40%
2026-08-11 1023997 390387 38.12%
2026-08-10 831186 342001 41.15%
2026-08-07 225240 45901 20.38%
2026-08-06 38010 20494 53.92%
2026-08-05 42472 20223 47.61%
2026-08-04 63211 31679 50.12%
2026-08-03 98125 51035 52.01%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers POLYMED.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
17 Aug 2023 RISHI BAID Director Sell Market Sale 24950 36774439 10.18% XBRL
14 Aug 2023 RISHI BAID Director Sell Market Sale 99264 146185779 10.21% XBRL
01 Apr 2022 RISHI BAID Director Sell Market Sale 30000 28308980 10.32% XBRL
29 Mar 2022 RISHI BAID Director Sell Market Sale 60000 50860424 10.35% XBRL
28 Mar 2022 RISHI BAID Director Sell Market Sale 10000 8469419 10.41% XBRL
01 Jul 2021 VCB TRADING LLP Promoter Group Sell Market Sale 100000 99500000 3.69% XBRL
11 Mar 2020 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Sell Market Sale 900 278520 0.04% XBRL
11 Mar 2020 NIDHI OSWAL (DAUGHTER OF CFO) Immediate relative Sell Market Sale 210 64981 0.00% XBRL
11 Mar 2020 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 450 130054 0.04% XBRL
27 Dec 2019 M/S. POLYCURE MARTECH LIMITED Promoter Group Buy Market Purchase 2000 413400 0.01% XBRL
23 Jul 2018 HIMANSHU BAID Promoters Sell Market Sale 167000 36561083 8.96% XBRL
23 Jul 2018 RISHI BAID Promoters Buy Market Purchase 167000 36561083 11.33% XBRL
09 Apr 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 300 77923 0.04%
09 Apr 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 71 18330 0.04%
25 Jan 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 650 168925 0.04%
23 Jan 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 1561 411681 0.04%
18 Sep 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Sell Market Sale 3459 827102 0.04%
02 Sep 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 1008 208876 0.05%
21 Aug 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 377 79074 0.04%
21 Aug 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 800 165942 0.04%

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers POLYMED.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹1719.40 INR (live) · fetched 2026-08-23 23:43 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Ratios

P/E
54.10
P/E = Price / EPS
P/E (Price to Earnings)

What the market pays today for one rupee of last year's profit.

P/E = Price ÷ (Net Income ÷ Diluted Shares Outstanding)

P/E divides the share price by earnings per share. If a share costs ₹300 and the company earned ₹15 per share, the P/E is 20 — buyers are paying twenty rupees for each rupee of annual profit.

A high P/E is not automatically 'expensive' and a low one is not automatically 'cheap'. A high number can mean the market expects profits to grow, or that the last year's profit was unusually low. A low number can mean the market expects profits to fall. P/E on its own says nothing about whether a price is justified — it is a starting question, not an answer.

P/E is undefined when a company made a loss, because dividing by a negative or zero profit produces a figure that cannot be read the normal way. StockProof shows N/A rather than a negative P/E.

In StockProof StockProof computes this from the latest cached price and the net income and diluted share count in the most recent filing on file. The historical P/E chart uses a different basis — filed annual EPS against an adjusted closing price — so the two figures are not directly comparable and are never differenced.

Introduction to the price-to-earnings ratio ↗ Khan Academy — external link, not StockProof content

Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹1,719.40 / (₹3,221,396,000 / 101,359,400 shares) = ₹1,719.40 / ₹31.78 EPS
FY2025-26 · Annual filing
ROE
10.37%
ROE = Net Income / Shareholder Equity
ROE (Return on Equity)

How much profit the company generated per rupee of shareholders' own money.

ROE = Net Income ÷ Shareholder Equity

ROE divides net income by shareholders' equity — the money owners have put in plus the profits kept in the business rather than paid out. An ROE of 18% means the business turned every ₹100 of owners' capital into ₹18 of annual profit.

ROE is flattered by debt. A company that funds itself heavily with borrowing has less equity in the denominator, so the same profit produces a higher ROE. Two companies with identical ROE can carry completely different risk, which is why ROE is read next to Debt/Equity rather than on its own — and why the DuPont decomposition below exists.

In StockProof Equity here is the figure filed in the most recent annual or quarterly statement. For banks and NBFCs the composite differs from a manufacturer's, which is why the source-trace line under each figure names the exact filed line item used.

DuPont decomposition

Splits ROE into three parts, so you can see whether it came from margin, efficiency, or debt.

ROE = (Net Income ÷ Revenue) × (Revenue ÷ Total Assets) × (Total Assets ÷ Equity)

The same ROE can be produced three very different ways. DuPont breaks it into Net Profit Margin × Asset Turnover × Equity Multiplier — how much profit each rupee of sales leaves, how much sales each rupee of assets generates, and how many rupees of assets sit on each rupee of equity.

A luxury brand reaches its ROE through margin. A supermarket reaches a similar ROE through turnover on thin margins. A leveraged lender reaches it through the equity multiplier. Only the third of those raises ROE by raising risk, and a single ROE number cannot tell you which of the three you are looking at.

This is why a rise in ROE is worth taking apart before it is treated as good news: an ROE that improved because the company borrowed more is a different fact from an ROE that improved because margins widened.

In StockProof StockProof does not yet render the three-way split as its own view — it is on the roadmap. The explanation is here because it is the right way to read the ROE figure shown beside it.

Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹3,221,396,000 / ₹31,061,727,000 = 10.37%
FY2025-26 · Annual filing
Debt/Equity
0.11
Debt/Equity = Total Debt / Shareholder Equity
Debt / Equity

How many rupees the company has borrowed for each rupee of owners' money.

Debt / Equity = Total Debt ÷ Shareholder Equity

A Debt/Equity of 0.5 means fifty paise of borrowing per rupee of equity; a figure of 2.0 means two rupees of borrowing per rupee of equity. It is the plainest single measure of how much of the business is funded by lenders rather than owners.

Borrowing is not itself a fault. It magnifies outcomes in both directions: the same leverage that lifts returns in a good year deepens losses in a bad one, and interest has to be paid whether or not the year was good. What counts as a lot depends entirely on the industry — a utility with contracted cash flows and a cyclical commodity producer are not comparable on this number.

Financial companies are the clearest case: for a bank or an NBFC, borrowing IS the raw material of the business, so a Debt/Equity that would be alarming for a manufacturer is ordinary for a lender.

In StockProof Both figures come from the same filing, so the ratio is internally consistent even when the filing itself is restated later.

Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹3,416,175,000 / ₹31,061,727,000 = 0.11
FY2025-26 · Annual filing
Current Ratio
3.37
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹19,417,332,000 / ₹5,755,224,000 = 3.37
FY2025-26 · Annual filing
ROCE
12.96%
ROCE = EBIT / (Shareholder Equity + Total Debt)
ROCE (Return on Capital Employed)

Return on ALL the long-term money in the business, borrowed as well as owned.

ROCE = EBIT ÷ (Total Equity + Total Debt)

ROCE divides operating profit (EBIT) by capital employed — equity plus debt. Where ROE asks what the owners earned, ROCE asks what the whole business earned on every rupee financed into it, whoever supplied that rupee.

Because the denominator includes debt, ROCE is not flattered by borrowing the way ROE is. That makes it the more comparable figure across companies with different capital structures, and the usual first check on whether a business is genuinely productive or merely leveraged.

A useful reference point is the company's own cost of borrowing: a business earning a ROCE below what it pays on its debt is consuming value on each additional rupee it employs.

In StockProof For lenders (banks, NBFCs, housing finance companies) the balance sheet has no current/non-current split and Finance Costs are close to a core operating cost rather than a financing item. StockProof still shows ROCE for those filers but prints an explicit caveat beside it — that caveat is not part of Learning Mode and shows whether or not this mode is on.

Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹4,468,821,000 / (₹31,061,727,000 + ₹3,416,175,000) = 12.96%
FY2025-26 · Annual filing
Dividend Yield
0.20%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹354,310,000 / 101,359,400 shares) / ₹1,719.40 = ₹3.50 / ₹1,719.40
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 18.9%
Net Profit (3y) 21.6%
Revenue (5y, 3.0y actual) 18.9%
Net Profit (5y) 21.6%
Revenue (10y, 3.0y actual) 18.9%
Net Profit (10y) 21.6%

Operating Margin Trend

Expanding

FY2022-23 21.9%
FY2023-24 25.7%
FY2024-25 27.5%
FY2025-26 23.8%

ROCE Trajectory

FY2022-23 17.6%
FY2023-24 21.5%
FY2024-25 15.6%
FY2025-26 12.8%

Earnings Quality

No persistent gap detected

Net Profit CAGR 21.57% vs CFO CAGR 8.04% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit -4.85% vs CFO -0.17%

Sector-Relative Percentile (Healthcare)

ROE 24th
ROCE 20th
Debt/Equity 50th
P/E 43th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹378.07 Cr. ₹384.78 Cr. ₹420.02 Cr. ₹424.21 Cr. ₹440.83 Cr. ₹403.21 Cr. ₹443.88 Cr. ₹493.66 Cr. ₹534.51 Cr. ₹525.38 Cr. RevenueFromOperations
Net Profit ₹68.36 Cr. ₹74.04 Cr. ₹87.45 Cr. ₹85.23 Cr. ₹91.83 Cr. ₹93.08 Cr. ₹91.83 Cr. incl. minority ₹91.80 Cr. ₹70.93 Cr. incl. minority ₹70.81 Cr. ₹66.29 Cr. incl. minority ₹65.04 Cr. ₹86.03 Cr. incl. minority ₹85.27 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers POLYMED.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent3221396000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital101359400.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets19417332000.0
CurrentLiabilities5755224000.0
EquityAttributableToOwnersOfParent31061727000.0
BorrowingsCurrent + BorrowingsNoncurrent3416175000.0

My notes